Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $452.60 million. The enterprise value is $357.98 million.

Market Cap	452.60M
Enterprise Value	357.98M

Important Dates

The next estimated earnings date is Tuesday, May 6, 2025, before market open.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Bionics has 43.35 million shares outstanding.

Current Share Class	43.35M
Shares Outstanding	43.35M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+6.41%
Owned by Insiders (%)	3.13%
Owned by Institutions (%)	14.54%
Float	36.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.02
Forward PS	5.31
PB Ratio	5.98
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.50
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.29, with a Debt / Equity ratio of 0.10.

Current Ratio	6.29
Quick Ratio	5.46
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -81.35% and return on invested capital (ROIC) is -38.72%.

Return on Equity (ROE)	-81.35%
Return on Assets (ROA)	-21.78%
Return on Invested Capital (ROIC)	-38.72%
Return on Capital Employed (ROCE)	-35.22%
Revenue Per Employee	$221,510
Profits Per Employee	-$186,245
Employee Count	294
Asset Turnover	0.50
Inventory Turnover	4.01

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	16.37
200-Day Moving Average	n/a
Relative Strength Index (RSI)	34.92
Average Volume (20 Days)	678,175

Short Selling Information

The latest short interest is 3.14 million, so 7.24% of the outstanding shares have been sold short.

Short Interest	3.14M
Short Previous Month	1.21M
Short % of Shares Out	7.24%
Short % of Float	8.62%
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $65.12 million and -$54.76 million in losses. Loss per share was -$8.60.

Revenue	65.12M
Gross Profit	35.89M
Operating Income	-45.25M
Pretax Income	-55.50M
Net Income	-54.76M
EBITDA	-44.10M
EBIT	-45.25M
Loss Per Share	-$8.60

Full Income Statement

Balance Sheet

The company has $103.58 million in cash and $7.26 million in debt, giving a net cash position of $96.32 million or $2.22 per share.

Cash & Cash Equivalents	103.58M
Total Debt	7.26M
Net Cash	96.32M
Net Cash Per Share	$2.22
Equity (Book Value)	76.01M
Book Value Per Share	-36.80
Working Capital	111.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$48.27 million and capital expenditures -$3.40 million, giving a free cash flow of -$51.67 million.

Operating Cash Flow	-48.27M
Capital Expenditures	-3.40M
Free Cash Flow	-51.67M
FCF Per Share	-$1.19

Full Cash Flow Statement

Margins

Gross margin is 55.11%, with operating and profit margins of -69.48% and -84.08%.

Gross Margin	55.11%
Operating Margin	-69.48%
Pretax Margin	-84.08%
Profit Margin	-84.08%
EBITDA Margin	-67.72%
EBIT Margin	-69.48%
FCF Margin	n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-12.05%
FCF Yield	-11.37%

Analyst Forecast

The average price target for Beta Bionics is $26.67, which is 155.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26.67
Price Target Difference	155.44%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Beta Bionics has an Altman Z-Score of -2.44 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.44
Piotroski F-Score	1